Motus GI Holdings Inc (NASDAQ:MOTS) has earned a consensus rating of “Buy” from the seven ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $10.63.
Several equities research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Motus GI from a “hold” rating to a “sell” rating in a report on Wednesday, July 18th. Oppenheimer set a $10.00 target price on shares of Motus GI and gave the stock a “buy” rating in a report on Wednesday, August 15th. Dougherty & Co assumed coverage on shares of Motus GI in a report on Tuesday, August 28th. They issued a “buy” rating and a $8.00 target price on the stock. Piper Jaffray Companies restated an “overweight” rating and issued a $8.00 target price on shares of Motus GI in a report on Tuesday, August 14th. Finally, LADENBURG THALM/SH SH assumed coverage on shares of Motus GI in a report on Thursday, August 30th. They issued a “buy” rating and a $14.50 target price on the stock.
Hedge funds have recently modified their holdings of the stock. IPG Investment Advisors LLC purchased a new stake in Motus GI in the second quarter worth approximately $106,000. Quantitative Systematic Strategies LLC bought a new position in Motus GI in the second quarter worth approximately $113,000. Private Advisor Group LLC bought a new position in Motus GI in the third quarter worth approximately $105,000. Renaissance Technologies LLC bought a new position in Motus GI in the third quarter worth approximately $139,000. Finally, Eaton Vance Management bought a new position in Motus GI in the third quarter worth approximately $204,000. Institutional investors own 21.74% of the company’s stock.
Motus GI (NASDAQ:MOTS) last issued its earnings results on Tuesday, August 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.01). The company had revenue of $0.03 million for the quarter. As a group, analysts expect that Motus GI will post -1.01 EPS for the current fiscal year.
About Motus GI
Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
Recommended Story: Does the discount rate affect the economy?
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.